Search research articles
Contact Us
Filters
Showing results (101-110 of 123) with videos related to
Page
of 13
Sort By:
The Journal of Clinical and Aesthetic Dermatology
|
December 19, 2025
Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series
Diego Ruiz Dasilva, Alondra Soto-González, Nicholas K Mollanazar, et al.
Dermatology and Therapy
|
August 9, 2024
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD
|
July 2, 2024
Appearance Dissatisfaction and Body Dysmorphic Disorder in the Dermatology Patient
Zane Sejdiu, Erin Stitzlein, Evan A Rieder, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Joshua Burshtein, April Armstrong, May Chow, et al.
The Journal of Clinical and Aesthetic Dermatology
|
February 6, 2026
PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology
Courtney A Chau, Hilary E Baldwin, James Q Del Rosso, et al.
Dermatology and Therapy
|
October 18, 2024
Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Pediatric Dermatology
|
February 15, 2013
Therapeutic patient education in atopic dermatitis: worldwide experiences
Jean-Francois Stalder, Claire Bernier, Alan Ball, et al.
JAMA Dermatology
|
August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
Clinical and Experimental Dermatology
|
November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population
Jonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 123) with videos related to
Sort By:
Page
of 13
The Journal of Clinical and Aesthetic Dermatology
|
December 19, 2025
Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series
Diego Ruiz Dasilva, Alondra Soto-González, Nicholas K Mollanazar, et al.
Dermatology and Therapy
|
August 9, 2024
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD
|
July 2, 2024
Appearance Dissatisfaction and Body Dysmorphic Disorder in the Dermatology Patient
Zane Sejdiu, Erin Stitzlein, Evan A Rieder, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Joshua Burshtein, April Armstrong, May Chow, et al.
The Journal of Clinical and Aesthetic Dermatology
|
February 6, 2026
PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology
Courtney A Chau, Hilary E Baldwin, James Q Del Rosso, et al.
Dermatology and Therapy
|
October 18, 2024
Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
Pediatric Dermatology
|
February 15, 2013
Therapeutic patient education in atopic dermatitis: worldwide experiences
Jean-Francois Stalder, Claire Bernier, Alan Ball, et al.
JAMA Dermatology
|
August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
Clinical and Experimental Dermatology
|
November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population
Jonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Page
of 13